[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR068529A1 - Uso de clec1b (lecitina tipo c de familia de dominio i, miembro b) - Google Patents

Uso de clec1b (lecitina tipo c de familia de dominio i, miembro b)

Info

Publication number
AR068529A1
AR068529A1 ARP080104114A ARP080104114A AR068529A1 AR 068529 A1 AR068529 A1 AR 068529A1 AR P080104114 A ARP080104114 A AR P080104114A AR P080104114 A ARP080104114 A AR P080104114A AR 068529 A1 AR068529 A1 AR 068529A1
Authority
AR
Argentina
Prior art keywords
clec1b
lecitine
thrombotic disorders
cardiovascular
type
Prior art date
Application number
ARP080104114A
Other languages
English (en)
Original Assignee
Dupuis Laurent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dupuis Laurent filed Critical Dupuis Laurent
Publication of AR068529A1 publication Critical patent/AR068529A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El uso del polimorfismo de un solo nucleotido (SNP) del gen CLEC1B para la identificacion de trastornos cardiovasculares y/o tromboticos o de un aumento del riesgo de desarrollar trastornos cardiovasculares y/o tromboticos en una muestra biologica extraída de un individuo bajo examen; el uso de CLEC1B para identificar sustancias activas para prevenir y/o tratar trastornos cardiovasculares y/o tromboticos, y métodos para ello; también se proporcionan un cebador de ácido nucleico (SEQ ID N° 4 o 5) y una zonda de ácido nucleico (SEQ ID N°: 3).
ARP080104114A 2007-09-24 2008-09-22 Uso de clec1b (lecitina tipo c de familia de dominio i, miembro b) AR068529A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07291134A EP2048243A1 (en) 2007-09-24 2007-09-24 Use of clec1B for the determination of cardiovascular and thrombotic risk

Publications (1)

Publication Number Publication Date
AR068529A1 true AR068529A1 (es) 2009-11-18

Family

ID=38765869

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104114A AR068529A1 (es) 2007-09-24 2008-09-22 Uso de clec1b (lecitina tipo c de familia de dominio i, miembro b)

Country Status (15)

Country Link
US (1) US20100311053A1 (es)
EP (3) EP2048243A1 (es)
JP (1) JP2010539891A (es)
KR (1) KR20100059897A (es)
CN (1) CN101809168A (es)
AR (1) AR068529A1 (es)
AT (1) ATE547706T1 (es)
AU (1) AU2008303866A1 (es)
BR (1) BRPI0817944A2 (es)
CA (1) CA2700219A1 (es)
IL (1) IL204557A0 (es)
MX (1) MX2010002993A (es)
SG (1) SG184704A1 (es)
TW (1) TW200934877A (es)
WO (1) WO2009040002A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2269597A1 (en) * 2009-06-22 2011-01-05 CSL Behring GmbH CLEC-2 is an essential platelet activating receptor in hemostasis and thrombosis
ES2627796T3 (es) * 2011-05-14 2017-07-31 Royal College Of Surgeons In Ireland Identificación de la trombosis o del riesgo de hemorragia en un individuo con y sin terapia antiplaquetaria
EP2592422A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
EP2592423A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
CN105112554B (zh) * 2015-09-28 2019-03-01 北京泱深生物信息技术有限公司 Clec1b基因在胆管癌诊断和治疗中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
EP1885872A4 (en) * 2005-04-25 2009-03-25 Univ Yamanashi COMPOSITIONS AND METHODS OF TREATING HEMOSTAS INTERFERENCE ASSOCIATED WITH CLEC-2 SIGNAL TRANSDUCTION
JP2007070359A (ja) * 2005-09-06 2007-03-22 Univ Of Yamanashi 止血疾患治療用の医薬組成物

Also Published As

Publication number Publication date
CA2700219A1 (en) 2009-04-02
IL204557A0 (en) 2010-11-30
JP2010539891A (ja) 2010-12-24
MX2010002993A (es) 2010-04-01
WO2009040002A1 (en) 2009-04-02
EP2048243A1 (en) 2009-04-15
KR20100059897A (ko) 2010-06-04
ATE547706T1 (de) 2012-03-15
SG184704A1 (en) 2012-10-30
CN101809168A (zh) 2010-08-18
EP2233584A1 (en) 2010-09-29
EP2195455A1 (en) 2010-06-16
US20100311053A1 (en) 2010-12-09
BRPI0817944A2 (pt) 2015-05-05
TW200934877A (en) 2009-08-16
AU2008303866A1 (en) 2009-04-02
EP2195455B1 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
UY31467A1 (es) Plantas y semillas de soja correspondientes al evento transgénico mon87701 y métodos de deteccion del mismo
ATE394674T1 (de) Funktionalisierte nanopartikel und verwendungsverfahren
NZ600376A (en) Elite event ee-gm3 and methods and kits for identifying such event in biological samples
Parekh et al. Aptamers recognizing glycosylated hemagglutinin expressed on the surface of vaccinia virus-infected cells
EA201000334A1 (ru) Улучшенное определение экспрессии mage-a
AR074135A1 (es) Adn genomico vegetal flanqueador de evento spt y metodos para identificar el evento de tecnologia de produccion de semillas (spt)
AR080009A1 (es) Alteracion genomica objetivo utilizando nucleasas de dedos de zinc
IN2012DN01800A (es)
MX356687B (es) Evento transgénico de frijol de soya mon87705 y métodos para detección del mismo.
MX2007009809A (es) Amplificacion de sonda por seleccion.
ES2531055T3 (es) Cebadores de polinucleótidos para detectar mutaciones de PIK3CA
JP2017501685A5 (es)
IN2012DN00403A (es)
AR068529A1 (es) Uso de clec1b (lecitina tipo c de familia de dominio i, miembro b)
AR127650A2 (es) Ácido nucleico aislado, método para determinar la cigosidad del adn de una planta de maíz que comprende el evento de maíz dp-004114-3, par de cebadores de polinucleótidos, kit y método para detectar la presencia de una molécula de ácido nucleico que es exclusiva del evento dp-004114-3
NZ601652A (en) Set of probes for the detection and typing of 46 human papillomavirus mucosal types
ES2623454T3 (es) Reducción del contenido de ácidos grasos saturados en semillas de plantas
AR078584A1 (es) Identificacion de microarn (miarn) en muestras fecales como biomarcador de canceres gastroenterologicos
MX2021008867A (es) Composiciones reactantes marcadas de intensidad alta y metodos de secuenciamiento.
JP2014530011A5 (es)
AR074961A1 (es) Genes asociados con el numero de retonos de plantas y sus usos.
PE20131401A1 (es) Kit para detectar el virus de la leucemia bovina (blv), y uso del mismo
EA201070229A1 (ru) Нуклеотидные последовательности msca1, влияющие на мужскую фертильность растений, и способ их применения
NZ602418A (en) Use of brown midrib-3 gene specific markers in maize for trait introgression
Yukhet et al. Isothermal detection of canine blood parasite (Ehrlichia canis) utilizing recombinase polymerase amplification coupled with graphene oxide quenching-based pyrrolidinyl peptide nucleic acid

Legal Events

Date Code Title Description
FA Abandonment or withdrawal